The SRC/ABL inhibitor BMS-354825 overcomes resistance to imatinib mesylate in chronic myelogenous leukemia cells through multiple mechanisms.

被引：4
|
作者：
Donato, NJ
Wu, J
Kong, LY
Lee, F
Talpaz, M
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Bristol Myers Squibb, Canc Therapeut, Princeton, NJ USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.1989.1989
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1989
引用
收藏
页码：549A / 549A
页数：1
相关论文
共 50 条
  • [1] Dasatinib (BMS-354825) overcomes multiple mechanisms of imatinib resistance in chronic myeloid leukemia (CML)
    Lee, FY
    Wen, ML
    Bhide, R
    Camuso, A
    Castenada, S
    Fager, K
    Flefleh, C
    Inigo, I
    Kan, D
    Luo, R
    Mcglinchey, K
    Smykla, R
    Wild, R
    Borzilleri, R
    Lombardo, L
    BLOOD, 2005, 106 (11) : 564A - 565A
  • [2] Mechanism of drug resistance to dasatinib (BMS-354825) and imatinib in chronic myelogenous leukemia cells.
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Broxmeyer, Hal E.
    Ohyashiki, Kazuma
    BLOOD, 2006, 108 (11) : 404A - 404A
  • [3] Cotreatment with vorinostat (Suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells
    Fiskus, Warren
    Pranpat, Michael
    Balasis, Maria
    Bali, Purva
    Estrella, Veronica
    Kumaraswamy, Sandhya
    Rao, Rekha
    Rocha, Kathy
    Herger, Bryan
    Lee, Francis
    Richon, Victoria
    Bhalla, Kapil
    CLINICAL CANCER RESEARCH, 2006, 12 (19) : 5869 - 5878
  • [4] Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia
    Donato, NJ
    Wu, JY
    Stapley, J
    Lin, H
    Arlinghaus, R
    Aggarwal, B
    Shishodin, S
    Albitar, M
    Hayes, K
    Kantarjian, H
    Talpaz, M
    CANCER RESEARCH, 2004, 64 (02) : 672 - 677
  • [5] The novel, dual Src/Bcr-Abl kinase inhibitor, BMS-354825, does not overcome the intrinsic insensitivity of quiescent chronic myeloid leukaemia stem cells to imatinib
    Copland, M
    Hamilton, A
    Barow, M
    Elrick, L
    Holyoake, TL
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 : 80 - 80
  • [6] Dynamics of molecular response to dasatinib (BMS-354825) in patients (pts) with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib.
    Quintas-Cardama, A.
    Kantarjian, H.
    Jones, D.
    Talpaz, M.
    Jabbour, E.
    O'Brien, S.
    Luthra, R.
    Wierda, W.
    Nicaise, C.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 343S - 343S
  • [7] Dasatinib (BMS-354825) inhibits stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells
    Nam, Sangkil
    Lee, Francis
    Jove, Richard
    CANCER RESEARCH, 2006, 66 (08)
  • [8] Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells
    Nam, Sangkil
    Williams, Ann
    Vultur, Adina
    List, Alan
    Halla, Kapil
    Smith, David
    Lee, Francis Y.
    Jove, Richard
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (04) : 1400 - 1405
  • [9] Dasatinib (BMS354825), a dual Src-Abl inhibitor, is active in Philadelphia chromosome-positive chronic myelogenous leukemia (Ph plus CML) following treatment failure with imatinib mesylate and AMN107.
    Estrov, Z.
    O'Brien, S.
    Giles, F.
    Garcia-Manero, G.
    Borthakur, G.
    Ravandi, F.
    Sams, I.
    Nicaise, C.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 344S - 344S
  • [10] Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
    Nam, S
    Lee, F
    Jove, R
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9029S - 9029S
12345